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A B S T R A C T
Background
The diagnosis of Alzheimer’s disease dementia and other dementias relies on clinical assessment. There is a high prevalence of cognitive
disorders, including undiagnosed dementia in secondary care settings. Short cognitive tests can be helpful in identifying those who
require further specialist diagnostic assessment; however, there is a lack of consensus around the optimal tools to use in clinical practice.
The Mini-Cog is a short cognitive test comprising three-item recall and a clock-drawing test that is used in secondary care settings.
Objectives
The primary objective was to determine the diagnostic accuracy of the Mini-Cog for detecting Alzheimer’s disease dementia and other
dementias in a secondary care setting. The secondary objectives were to investigate the heterogeneity of test accuracy in the included
studies and potential sources of heterogeneity. These potential sources of heterogeneity will include the baseline prevalence of dementia
in study samples, thresholds used to determine positive test results, the type of dementia (Alzheimer’s disease dementia or all causes of
dementia), and aspects of study design related to study quality.
Search methods
We searched the following sources in September 2012, with an update to 12 March 2019: Cochrane Dementia Group Register of
Diagnostic Test Accuracy Studies, MEDLINE (OvidSP), Embase (OvidSP), BIOSIS Previews (Web of Knowledge), Science Citation
Index (ISI Web of Knowledge), PsycINFO (OvidSP), and LILACS (BIREME). We made no exclusions with regard to language of
Mini-Cog administration or language of publication, using translation services where necessary.
Selection criteria
We included cross-sectional studies and excluded case-control designs, due to the risk of bias. We selected those studies that included the
Mini-Cog as an index test to diagnose dementia where dementia diagnosis was confirmed with reference standard clinical assessment
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using standardised dementia diagnostic criteria. We only included studies in secondary care settings (including inpatient and outpatient
hospital participants).
Data collection and analysis
We screened all titles and abstracts generated by the electronic database searches. Two review authors independently checked full papers
for eligibility and extracted data. We determined quality assessment (risk of bias and applicability) using the QUADAS-2 tool. We
extracted data into two-by-two tables to allow calculation of accuracy metrics for individual studies, reporting the sensitivity, specificity,
and 95% confidence intervals of these measures, summarising them graphically using forest plots.
Main results
Three studies with a total of 2560 participants fulfilled the inclusion criteria, set in neuropsychology outpatient referrals, outpatients
attending a general medicine clinic, and referrals to a memory clinic. Only n = 1415 (55.3%) of participants were included in the
analysis to inform evaluation of Mini-Cog test accuracy, due to the selective use of available data by study authors. There were concerns
related to high risk of bias with respect to patient selection, and unclear risk of bias and high concerns related to index test conduct and
applicability. In all studies, the Mini-Cog was retrospectively derived from historic data sets. No studies included acute general hospital
inpatients. The prevalence of dementia ranged from 32.2% to 87.3%. The sensitivities of the Mini-Cog in the individual studies were
reported as 0.67 (95% confidence interval (CI) 0.63 to 0.71), 0.60 (95% CI 0.48 to 0.72), and 0.87 (95% CI 0.83 to 0.90). The
specificity of the Mini-Cog for each individual study was 0.87 (95% CI 0.81 to 0.92), 0.65 (95% CI 0.57 to 0.73), and 1.00 (95% CI
0.94 to 1.00). We did not perform meta-analysis due to concerns related to risk of bias and heterogeneity.
Authors’ conclusions
This review identified only a limited number of diagnostic test accuracy studies using Mini-Cog in secondary care settings. Those
identified were at high risk of bias related to patient selection and high concerns related to index test conduct and applicability. The
evidence was indirect, as all studies evaluated Mini-Cog differently from the review question, where it was anticipated that studies would
conduct Mini-Cog and independently but contemporaneously perform a reference standard assessment to diagnose dementia. The
pattern of test accuracy varied across the three studies. Future research should evaluate Mini-Cog as a test in itself, rather than derived
from other neuropsychological assessments. There is also a need for evaluation of the feasibility of the Mini-Cog for the diagnosis of
dementia to help adequately determine its role in the clinical pathway.
P L A I N L A N G U A G E S U M M A R Y
How accurate is the Mini-Cog in detecting dementia among patients in inpatient and outpatient hospital settings?
Why is recognising dementia important?
Dementia is a common and important condition, and many of those living with dementia have never had the condition diagnosed.
Diagnosis provides opportunities for social support, advance care planning and, in specific disease types, treatment with medication.
However, incorrectly diagnosing dementia when it is not present (a false-positive result) can be distressing for the individual and their
family and lead to a waste of resources in diagnostic tests.
What was the aim of the review?
The aim of this Cochrane Review was to find out how accurate the Mini-Cog test is for detecting dementia among patients in inpatient
and outpatient hospital settings. The researchers included three studies to answer this question.
What was studied in the review?
The Mini-Cog is a short test of memory and thinking skills that tests the ability of an individual to remember three specific objects,
named at the beginning of a short assessment, repeated at the time and recalled by the individual later. In addition, the individual
being assessed is asked to draw a clock face at a specific time. Points are scored based on the ability to recall the three items and the
completeness of the clock. The Mini-Cog is a short test that would typically be used to identify if someone was having difficulty with
memory and thinking skills who would benefit from referral to a specialist for more detailed assessment.
What are the main results of the review?
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The review included data from three relevant studies with a total of 2560 participants. However, the study authors did not use data
from many of those participants they assessed, leaving results from only 1415 participants that provide complete and useful information
for addressing the review question.
All three studies scored the Mini-Cog results in the way that was recommended by the developers of the tool. There was no clear
pattern in the results of what a positive result of a Mini-Cog test meant across the three studies, making it difficult to draw summary
conclusions. Using the studies with the highest and lowest Mini-Cog results indicated that if the Mini-Cog were to be used in secondary
care in a group of 1000 people, where 640 (64%) have dementia, an estimated 510 to 557 would have a positive Mini-Cog, of which
0 to 126 would be incorrectly classified as having dementia. Of the 443 to 490 people with a result indicating dementia is not present,
83 to 256 would be incorrectly classified as not having dementia.
How reliable are the results of the studies in the review?
In the included studies, the diagnosis of dementia was made by assessing all patients with a detailed clinical assessment. Detailed clinical
assessment is the reference standard to which the Mini-Cog was compared. This is likely to have been a reliable method for determining
whether patients actually had dementia. However, there were some problems with how the studies were conducted in terms of the
people who were included and how the Mini-Cog was calculated, which could result in the Mini-Cog appearing more accurate than it
actually is. We decided that it was not appropriate to group the studies together to describe the average performance of the Mini-Cog,
due to the differences among them.
To whom do the results of this review apply?
The studies included in the review were conducted in the USA, Germany, and Brazil. Two studies included those patients referred
to specialists evaluating memory and thinking skills, and one study recruited individuals attending a medical outpatient clinic. The
percentage of people with a final diagnosis of dementia was between 32% and 87% (an average of 64%).
What are the implications of this review?
The small number of studies identified and variation in how they used the Mini-Cog limit the evidence to make recommendations,
and suggest that Mini-Cog may not be the best test to recommend for use in inpatient and outpatient secondary care hospital settings.
How up-to-date is this review?
The review authors searched for and considered studies published up to March 2019.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
What is the accuracy of the Mini-Cog for the diagnosis of Alzheimer’s disease dementia and other dementias within a secondary care setting?
Population Adult pat ients who completed the Mini-Cog, with no restrict ions on the case mix of recruited part icipants
Setting Secondary care sett ings including outpat ient clinics, inpat ient general, and specialist hospital sett ings
Index test Mini-Cog includes the Clock Draw Tests and 3-word recall
Reference standard Clinical diagnosis of dementia using recognised diagnost ic criteria
Studies Cross-sect ional but not case-control studies were included
Study Summary accuracy
(95% CI)
No. of included
participants
Dementia
prevalence
Implications, quality, and comments
Clionsky 2010 scoring as per
Borson 2000
Sensit ivity: 0.67 (0.63 to 0.71)
Specif icity: 0.87 (0.81 to 0.92)
Posit ive PV: 0.94
Negative PV: 0.49
702 73.5% Only 40% of available records collated f rom neu-
ropsychology and geriatric psychiatry pract ice
were used to evaluate Mini-Cog accuracy. Sam-
pling f rame, inclusion and exclusion criteria were
not described. M ini-Cog derived f rom longer cog-
nit ive test battery. Included all-cause dementia
and reported dementia subtypes diagnosed
Patient select ion - high risk of bias; unclear appli-
cability concerns
Index test - unclear risk of bias; high applicability
concerns
Reference standard - low risk of bias; low appli-
cability concerns
Flow and tim ing - high risk of bias
Filho 2009 mult iple thresholds re-
ported in paper; data quoted with
scoring as per Borson 2000
Sensit ivity: 0.60 (0.48 to 0.72)
Specif icity: 0.65 (0.57 to 0.73)
Posit ive PV: 0.45
Negative PV: 0.78
211 32.2% Mult iple exclusion criteria including relying on par-
t icipants providing informed consent. Only 69%
of assessed part icipants included in the analysis.
Focused on those who had 4 or fewer years of ed-
ucat ion. M ini-Cog derived f rom longer cognit ive
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test battery. Did not report dementia by subtype
diagnosed
Patient select ion - high risk of bias; high applica-
bility concerns
Index test - unclear risk of bias; high applicability
concerns
Reference standard - low risk of bias; low appli-
cability concerns
Flow and tim ing - high risk of bias
Milian 2012 scoring as per Borson
2000
Sensit ivity: 0.87 (0.83 to 0.90)
Specif icity: 1.00 (0.94 to 1.00)
Posit ive PV: 1.00
Negative PV: 0.52
502 87.3% Included individuals admitted to Specialist Mem-
ory Clinic sett ing, but excluded those with de-
pression and mild cognit ive impairment which ac-
counts for very high prevalence of dementia. M ini-
Cog derived f rom longer cognit ive test battery. In-
cluded all-cause dementia and reported dementia
subtypes diagnosed
Patient select ion - high risk of bias; high applica-
bility concerns
Index test - unclear risk of bias; high applicability
concerns
Reference standard - low risk of bias; low appli-
cability concerns
Flow and tim ing - low risk of bias
95%CI: 95% conf idence interval
Posit ive PV: posit ive predict ive value
Negative PV: negat ive predict ive value
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B A C K G R O U N D
Target condition being diagnosed
Alzheimer’s disease (AD) and related forms of dementia are com-
mon among older adults, with a prevalence of 8% in individuals
over age 65 years, increasing to a prevalence of approximately 43%
in adults aged 85 years and older (Thies 2012). Given the increas-
ing number of older adults in most low and middle income coun-
tries, the prevalence of dementia is expected to increase consider-
ably in the coming years (Prince 2016). Currently, an estimated
5.4 million Americans are diagnosed with AD, and this num-
ber is expected to increase to 6.7 million by 2025 (Thies 2012).
Alzheimer’s disease and related forms of dementia are currently
incurable and result in considerable direct and indirect costs, both
in terms of formal health care and lost productivity from both the
affected individual and their caregivers (Thies 2012). There are
several potential benefits to diagnosing AD and other dementias
early in the disease course. Earlier diagnosis of AD allows for in-
dividuals with AD to make decisions regarding future planning
whilst they retain the capacity to do so (Prorok 2013). A diag-
nosis of dementia is also necessary to access certain services and
supports for individuals and their caregivers, and pharmacological
treatments such as cholinesterase inhibitors or memantine may
provide temporary symptomatic improvement in cognitive and
functional symptoms for individuals with mild to moderate AD
(Birks 2015; Birks 2018; McShane 2019; Rolinski 2012). There
has been a relative lack of research exploring whether proactive
case-finding for dementia is cost-effective and the impact on those
referred for specialist assessment (Robinson 2015).
The diagnosis of AD is clinical and based on a history of decline
in cognition with deficits in memory and at least one other area
of cognitive functioning (e.g. apraxia, agnosia, or executive dys-
function). There must be a decline from a previous level of func-
tioning that results in significant social or occupational impair-
ment (American Psychiatric Association 2000; McKhann 2001).
A definitive diagnosis of AD can only be achieved at autopsy, but
a clinical diagnosis using standardised criteria is associated with
a sensitivity of 81% and a specificity of 70% when compared to
autopsy-proven cases (Knopman 2001).
Approximately 50% to 80% of all individuals with dementia are
ultimately classified as AD (Blennow 2006; Brunnstrom 2009;
Canadian Study of Health and Aging 1994). Whilst individuals
with dementias share common characteristics, subtle differences
can help to provide a diagnosis in the absence of neuropatholog-
ical examination. Vascular dementias may occur more abruptly
or present with a step-wise decline in cognitive functions over
time, and account for approximately 15% to 20% of dementias
(Canadian Study of Health and Aging 1994; Feldman 2003; Lobo
2000). Dementia with a mixed vascular and Alzheimer’s disease
pathology is present in 10% to 30% of cases (Brunnstrom 2009;
Crystal 2000; Feldman 2003). A smaller proportion of dementias
are associated with dementia with Lewy bodies, Brunnstrom 2009,
or Parkinson’s disease dementia (Aarsland 2005). Individuals ex-
periencing frontotemporal dementia account for a smaller propor-
tion of dementias (4% to 8%) and often present with problems
in executive function and changes in behaviour, whilst memory is
relatively preserved early in the disease course (Brunnstrom 2009;
Greicius 2002).
Index test(s)
The Mini-Cog is a brief cognitive test consisting of two com-
ponents: a delayed three-word recall and the clock-drawing test
(Borson 2000). The Mini-Cog was initially developed in a com-
munity setting to provide a relatively brief cognitive screening test
that was free of educational and cultural biases (Borson 2000).
Different scoring algorithms were tested to determine which com-
bination had the optimal balance of sensitivity and specificity
(McCarten 2011; Scanlan 2001). The Mini-Cog takes approx-
imately three to five minutes to complete in routine practice
(Borson 2000; Holsinger 2007; Scanlan 2001). The Mini-Cog has
been reported to have little potential for bias with education or
language (Borson 2000; Borson 2005).
Clinical pathway
Dementia typically begins with subtle cognitive changes and pro-
gresses gradually over the course of several years. There is a pre-
sumed period when people are asymptomatic although the disease
pathology may be progressing (Ritchie 2015). Individuals or their
relatives may first notice subtle impairments of short-term mem-
ory or other areas of cognitive functioning. Gradually, the severity
of cognitive deficits becomes apparent resulting in difficulty com-
pleting complex activities of daily living such as management of
finances and medications, or operating motor vehicles (Njegovan
2001; Pérès 2008). The attribution of cognitive symptoms to nor-
mal aging may cause delays in the diagnosis and treatment of AD
or other types of dementia (Koch 2010). Consequently, there is a
need for accurate brief cognitive screening tests to help distinguish
between the cognitive changes associated with normal aging and
changes that might indicate a dementia.
Cognitive assessment in a secondary care setting occurs in two
broad contexts. Either individuals are referred from primary care
or community health services for further evaluation of possible
memory complaints. Alternatively, individuals may have their cog-
nition evaluated as part of a comprehensive assessment of care
needs following an acute, unscheduled hospitalisation. As a conse-
quence, those assessed in secondary care settings would likely have
some cognitive complaints or symptoms at the time of evaluation.
Previous estimates suggest that 16% of those attending memory
clinic had no cognitive impairments (Pusswald 2013), and 62%
of hospitalised older adults had no cognitive impairment (Reynish
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2017). Secondary care settings that may use the Mini-Cog or other
screening tests would include neurology, geriatric medicine, geri-
atric psychiatry services, or memory clinics. Typically, individuals
who are assessed in secondary care settings would receive more de-
tailed neuropsychological testing along with other investigations
that are needed in order to confirm a diagnosis of dementia.
Prior test(s)
Mini-Cog is recommended for use as an initial screening test for
dementia, therefore it is unlikely that individuals will have any
formal testing completed prior to the administration of the Mini-
Cog. The extent of any prior cognitive assessment may vary de-
pending on source of referral (Fisher 2007).
Role of index test(s)
Most older adults with memory complaints will first present to
their general practitioner or other primary healthcare provider
(e.g. nurses or a nurse practitioner). Primary healthcare providers
may then refer an individual to a secondary care setting such as
a neurologist, geriatrician, or geriatric psychiatrist. Some coun-
tries have also recommended that brief cognitive screening tests
be administered to all older adults in order to help screen for un-
detected or asymptomatic cognitive impairment (Cordell 2013),
although routine screening of older adults for dementia is con-
troversial (Martin 2015). We would anticipate that the Mini-Cog
would be utilised as a screening test to guide further evaluation of
cognitive complaints for individuals in secondary care and not as
a diagnostic test in most instances.
Alternative test(s)
The Cochrane Dementia and Cognitive Improvement Group
(CDCIG) have conducted a series of diagnostic test accuracy re-
views of cognitive tests, biomarkers, and informant tools, as a
planned programme of reviews (Davis 2013). This review focused
only on the test accuracy of Mini-Cog, and alternative tests are
not included as they have been examined in separate reviews.
Rationale
Cognitive diagnostic tests are required to assess cognition and as-
sist in diagnosing conditions such as mild cognitive impairment
and dementia. Comprehensive evaluation, conducted by psychol-
ogists or dementia specialists such as general psychiatrists, geriatric
psychiatrists, geriatricians, or neurologists, using standardised di-
agnostic criteria, would be the reference standard for assessing cog-
nition and diagnosing dementia in older adults. However, access
to these specialised resources is scarce and expensive, and as such
they are not practical for routine use in the evaluation of cogni-
tive complaints (Pimlott 2009; Yaffe 2008). Whilst there are some
cognitive tests that can be performed by healthcare providers who
are not dementia specialists, many of these tests are time consum-
ing and may not be practical to use as a first-line cognitive screen
in secondary care settings. As such, brief but relatively accurate
cognitive screening tests are required for healthcare providers in
secondary care settings to identify individuals who may require
more in-depth evaluation of cognition. In secondary care settings,
brief cognitive screening tests may be used to guide subsequent
evaluations or to complement more detailed evaluations.
Utilising a standard cognitive screening test like the Mini-Cog also
promotes effective communication between healthcare providers.
Sensitivity and specificity of such tests vary depending upon the
setting in which they are used (Holsinger 2007). Some studies have
found that in primary care the majority of older adults with demen-
tia are undiagnosed (Boustani 2005; Sternberg 2000). In addition,
many primary care providers have difficulty in accurately diagnos-
ing dementia, and mild dementia in particular is underdiagnosed
(van den Dungen 2011). Early diagnosis and treatment of demen-
tia can have clinical benefits for the patient, their community, and
the healthcare system (Bennett 2003; Prorok 2013; Thies 2012).
Accurate diagnosis of dementia is also important in order to ini-
tiate dementia therapeutics including both non-pharmacological
treatments and pharmacological treatments such as cholinesterase
inhibitors, Birks 2015; Birks 2018; Rolinski 2012, or meman-
tine (McShane 2019). A brief and simple cognitive screening test
such as the Mini-Cog that could be used in secondary care set-
tings would allow healthcare professionals or lay people to initially
screen older adults for the presence of dementia. Individuals that
screen positive for cognitive impairment on the Mini-Cog may
then be further investigated for the presence of dementia using
additional cognitive tests or other investigations. As Mini-Cog is
brief, widely available, easy to administer, and has been reported
to have reasonable test accuracy properties (Brodaty 2006; Lin
2013), it may be well suited for use as an initial cognitive screening
test in secondary care. The Mini-Cog has been recommended as a
suitable cognitive screening test for primary care in some countries
(Cordell 2013). The current review examined the diagnostic ac-
curacy of the Mini-Cog in secondary care settings. Separate DTA
reviews have been undertaken evaluating the use of Mini-Cog in
community and primary care settings (Fage 2015; Seitz 2018).
O B J E C T I V E S
To determine the diagnostic accuracy of the Mini-Cog for detect-
ing Alzheimer’s disease dementia and other dementias in a sec-
ondary care setting.
Secondary objectives
To investigate the heterogeneity of test accuracy in the included
studies and potential sources of heterogeneity. These potential
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sources of heterogeneity will include the baseline prevalence of
dementia in study samples, thresholds used to determine positive
test results, the type of dementia (Alzheimer’s disease dementia or
all causes of dementia), and aspects of study design related to study
quality.
We identified gaps in the evidence where further research is re-
quired.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included all cross-sectional studies with well-defined popula-
tions that utilised the Mini-Cog as an index cognitive screening
test compared to a reference standard to identify dementia. In-
cluded studies also utilised the Mini-Cog as a screening test and
not for confirmation of diagnosis. We excluded case-control stud-
ies and longitudinal designs in which there was a gap of more than
four weeks between administration of the index test and reference
standard.
Participants
Study participants were sampled from a secondary care setting and
may or may not have ultimately been diagnosed with AD or other
dementias. Participants may have had cognitive complaints or de-
mentia at baseline, although their cognitive status should not be
known to the individual administering the Mini-Cog or the refer-
ence standard. We excluded studies on participants with a devel-
opmental disability which prevented them from completing the
Mini-Cog. Secondary care settings included inpatient and outpa-
tient hospital participants. We excluded studies including partic-
ipants in either a community or primary care setting, as these are
topics of other reviews (Fage 2015; Seitz 2018).
Index tests
Mini-Cog test
The Mini-Cog consists of a three-word recall task and the clock-
drawing test. The standard scoring system involves assigning a
score of zero to three points on the word recall task for the correct
recall of 0, 1, 2, or 3 words, respectively. The clock-drawing test
is scored as being either ’normal’ or ’abnormal’. A positive test on
the Mini-Cog (that is dementia) is assigned if either the delayed
word recall score is zero out of three, or if the delayed recall score is
either one or two, and the clock-drawing test is abnormal. A score
of three on the delayed word recall or one to two on the delayed
word recall with a normal clock drawing is a negative test (i.e. is
no dementia) (Borson 2000).
Studies had to include the results of the Mini-Cog. Where multiple
scoring algorithms were utilised, we explored the differences in
results in subgroup analysis. We anticipated that the Mini-Cog
would be utilised as a screening test to guide further evaluation of
cognitive complaints for individuals in secondary care and not as
a diagnostic test in most instances.
Target conditions
Target conditions included any stage of AD or other types of de-
mentia including vascular dementia, dementia with Lewy bodies,
Parkinson’s disease dementia, or frontotemporal dementia.
Reference standards
Whilst a definitive diagnosis can only be made postmortem at au-
topsy, there are clinical criteria for the diagnosis of most forms of
dementia. All dementia diagnostic criteria require that an individ-
ual has deficits in multiple areas of cognition that results in impair-
ment in daily functioning and is not caused by either the effects
of a substance or a general medical condition. We describe poten-
tial reference standards for the diagnosis of all-cause dementia or
specific types of dementia. All-cause dementia is commonly diag-
nosed using criteria such as the Diagnostic and Statistical Manual
of Mental Disorders IV (DSM-IV) criteria for dementia (American
Psychiatric Association 2000), the DSM-5 criteria for major neu-
rocognitive disorder (American Psychiatric Association 2013), or
the International Classification of Diseases (ICD) diagnosis of de-
mentia (World Health Organization 2016). The standard clini-
cal diagnostic criteria commonly used for Alzheimer’s disease de-
mentia include the National Institute of Neurological and Com-
municative Disorders and Stroke and the Alzheimer’s Disease and
Related Disorders Association (NINCDS-ADRDA) criteria for
probable or possible dementia (McKhann 1984; McKhann 2011).
Diagnostic criteria for other types of dementia include the Na-
tional Institute of Neurological Disorders and Stroke and Associa-
tion Internationale pour la Recherché et l’Enseignement en Neuro-
sciences (NINDS-AIREN) criteria for vascular dementia (Roman
1993), standard criteria for dementia with Lewy bodies (McKeith
2005), and for frontotemporal dementia (McKhann 2001). Eval-
uation often includes laboratory investigations, many of which are
useful for excluding alternative diagnoses (Feldman 2008).
Additional procedures to help confirm the diagnosis include spe-
cific findings on neuroimaging (either computed tomography
(CT) or magnetic resonance imaging (MRI)). These investigations
are typically used to confirm the diagnosis rather than rule out
the possibility of dementia. Whilst these clinical criteria for de-
mentia are considered the reference standard for the purposes of
our review, the sensitivity and specificity of these clinical reference
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standards may vary when compared to neuropathological criteria
for dementia (Nagy 1998).
Search methods for identification of studies
Electronic searches
We searched the Cochrane Dementia Group Register of Di-
agnostic Test Accuracy Studies, MEDLINE (OvidSP), Embase
(OvidSP), BIOSIS Citation Index (ISI Web of Science), Web
of Science Core Collection Science Citation Index (ISI Web of
Science), PsycINFO (OvidSP), and LILACS (BIREME) (Latin
American and Caribbean Health Science Information database).
See Appendix 1 for the search strategy used and to view the ’generic’
search that is run regularly for the Cochrane Dementia and Cog-
nitive Improvement Group Register of Diagnostic Test Accuracy
Studies. Controlled vocabulary such as MeSH terms and Emtree
were used where appropriate. In order to maximise sensitivity and
allow inclusion on the basis of population-based sampling to be as-
sessed at testing (see Selection of studies), there was no attempt to
restrict studies based on sampling frame or setting in the searches
that were developed. We did not use search filters (collections of
terms aimed at reducing the number needed to screen) as an overall
limiter because those published have not proved sensitive enough
(Whiting 2011). We applied no language restriction to the elec-
tronic searches, and used translation services as necessary.
A single review author with extensive experience in systematic
reviews performed the initial searches (ANS). Two review authors
independently screened abstracts and titles.
Searching other resources
We searched the reference lists of all relevant studies for addi-
tional relevant studies. These studies were also used to search the
electronic databases to identify additional studies through the use
of the related article feature. We asked research groups authoring
studies used in the analysis for any unpublished data.
Data collection and analysis
Selection of studies
Included studies had to:
1. make use of the Mini-Cog as a cognitive diagnostic tool;
2. include patients from a secondary care setting who may or
may not have dementia or cognitive complaints. We did not
include case-control studies;
3. clearly explain how a diagnosis of dementia was confirmed
according to a reference standard such as the Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition Text
Revision (DSM IV-TR) or NINCDS-ADRDA at the same time
or within the same four-week period that the Mini-Cog was
administered. Formal neuropsychological evaluation was not
required for a diagnosis of dementia.
We first selected articles on the basis of abstracts and titles. We
retrieved the full texts of those articles deemed potentially eligible,
and two review authors independently assessed these for inclusion
in the review. Any disagreements were settled by consulting a third
review author.
Data extraction and management
Two review authors extracted the following data from all included
studies.
• Author, journal, and year of publication.
• Scoring algorithm for the Mini-Cog including cut-points
used to define a positive screen.
• Method of Mini-Cog administration including who
administered and interpreted the test, their training, and
whether or not the readers of the Mini-Cog and reference
standard were blind (masked) to the results of the other test.
• Reference criteria and method used to confirm diagnosis of
AD or other dementias.
• Baseline demographic characteristics of the study
population including age, gender, ethnicity, spectrum of
presenting symptoms, comorbidity, educational achievement,
language, baseline prevalence of dementia, country,
apolipoprotein E (ApoE) status, methods of participant
recruitment, and sampling procedures.
• Length of time between administration of index test (Mini-
Cog) and reference standard.
• The true positives, true negatives, false positives, false
negatives, disease prevalence, sensitivity and specificity, and
positive and negative likelihood ratios of the index test in
defining dementia.
• Version of translation (if applicable).
• Prevalence of dementia in the study population.
• Estimates of test reproducibility (if available).
Assessment of methodological quality
We used the Quality Assessment of Diagnostic Accuracy Studies
(QUADAS-2) criteria to assess data quality (Whiting 2011). The
QUADAS-2 criteria contain assessment domains for patient selec-
tion, index test, reference test, and flow and timing. Each domain
has suggested signalling questions to assist with the ’Risk of bias’
assessment for each domain (Appendix 2). The potential risk of
bias associated with each domain is rated as being at high, low, or
uncertain risk of bias. In addition, we performed an assessment
of the applicability of the study to the review question for each
domain using the guide provided in the QUADAS-2. We used
a standardised ’Risk of bias’ template to extract data on the risk
9Mini-Cog for the diagnosis of Alzheimer’s disease dementia and other dementias within a secondary care setting (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
of bias for each study using the form provided by the UK Sup-
port Unit Cochrane Diagnostic Test Accuracy Group (Appendix
3). We summarised the quality assessment results graphically and
presented a narrative summary in the Results.
Statistical analysis and data synthesis
We performed statistical analysis as per the Cochrane guidelines
for diagnostic test accuracy reviews (Macaskill 2010). Two-by-two
tables were constructed separately for the Mini-Cog results for
Alzheimer’s disease dementia and all-cause dementia where this
information was available.
We entered data from the individual studies into Review Manager
5 (Review Manager 2014). We used reported data on test accuracy
and disease prevalence or the true positives (TP), true negatives
(TN), false positives (FP), and false negatives (FN), whichever
was reported by the individual study. We calculated the sensitivity,
specificity, and positive and negative likelihood ratios as well as
measures of statistical uncertainty (e.g. 95% confidence intervals).
We presented data from each study graphically by plotting sensi-
tivities and specificities on a coupled forest plot.
We did not conduct our prespecified statistical analysis, using bi-
variate random-effects for meta-analysis due to concerns related
to methodological and clinical heterogeneity across the included
studies.
Investigations of heterogeneity
The potential sources of heterogeneity included baseline preva-
lence of cognitive impairment in the target population, the cut-
points used to determine a positive test result, the reference stan-
dard used to diagnose dementia, the type of dementia (Alzheimer’s
disease dementia or all-cause dementia), the severity of dementia
in the study sample, and aspects related to study quality. We have
presented narrative results where data were available to describe
the between-study heterogeneity.
Sensitivity analyses
We planned to conduct sensitivity analyses to investigate study
quality and the impact on overall diagnostic accuracy of Mini-
Cog. We did not perform this analysis given the methodological
concerns with all three of the identified studies. We also did not
evaluate the impact of individual studies on summary outcome
measures, as it was not considered appropriate to calculate a sum-
mary measure from the data in the three studies due to their het-
erogeneity.
Assessment of reporting bias
We did not investigate reporting bias because of current uncer-
tainty about how it operates in test accuracy studies and the in-
terpretation of existing analytical tools such as funnel plots (van
Enst 2014).
R E S U L T S
Results of the search
The results of the literature search are summarised in Figure 1.
An initial review of the electronic databases in September 2012
identified 108 articles. We updated this search in January 2013,
adding an additional 106 articles, and completed a second update
in February 2015 that identified another 34 potentially relevant
citations. The same search strategy was employed for this review
that was used in separate reviews of the Mini-Cog in the commu-
nity setting and the primary care setting (Fage 2015; Seitz 2018).
We performed a final update search for this review only in March
2019, which identified 324 articles. After removal of duplicates,
two review authors independently reviewed a total of 468 abstracts
and citations to determine those that were potentially eligible. We
reviewed a total of 62 full-text articles for eligibility, of which 59
were excluded. Reasons for exclusions were: a lack of a reference
standard (N = 20), incorrect setting (N = 14), duplicate publica-
tions (N = 12), failure to include the Mini-Cog as an index text (N
= 5), wrong study design (N = 4), not using Mini-Cog to diagnose
dementia (N = 3), and lack of sufficient data to be included in in
the review (N = 1). We included three studies in the review.
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Figure 1. Study flow diagram.
11Mini-Cog for the diagnosis of Alzheimer’s disease dementia and other dementias within a secondary care setting (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Methodological quality of included studies
The results of the QUADAS-2 assessment for the three included
studies are presented graphically in Figure 2.
Figure 2. Risk of bias and applicability concerns summary: review authors’ judgements about each domain
for each included study.
We considered all studies at high risk of bias with respect to pa-
tient selection. This was as a result of non-consecutive samples
or exclusion of records available for inclusion. There were high
applicability concerns with respect to patient selection from two
of the studies (Filho 2009; Milian 2012). These were as a result of
excluding those patients with common and important conditions,
such as depression or mild cognitive impairment, the exclusion of
those with sensory impairments, and the need for some partici-
pants to provide informed consent to participate. The inclusion/
exclusion criteria for Clionsky 2010 were not reported in the pa-
per, rendering assessment of applicability as at unclear risk.
An additional feature common to all the included studies was
the way the index test was performed and evaluated. All studies
retrospectively derived the Mini-Cog using responses to the three-
word recall and clock-drawing test that were collected as part of a
larger and longer battery of neuropsychological tests. The accuracy
of the Mini-Cog may have been affected when the result of the
Mini-Cog stemmed from more comprehensive testing compared
to when the component tests were administered by themselves. As
such we rated all studies as at unclear risk of bias for the index test
domain and as at high concern regarding the applicability of the
results, given that this is not how short cognitive index tests would
typically be performed.
In all cases we considered that the reference standard used was
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likely to correctly identify the target condition, and the risk of bias
associated with this was low and applicability concerns were low.
However, there are risks of incorporation bias if the assessments
used to derive the Mini-Cog were known to those making the
reference standard diagnosis.
We assessed two studies as high risk in the flow and timing domain
due to use of multiple reference standards, Clionsky 2010, and
selective use of data (Clionsky 2010; Filho 2009). We considered
one study as at low risk of bias for the flow and timing domain
(Milian 2012).
Findings
We included three papers in the final review (Clionsky 2010; Filho
2009; Milian 2012). The study population included in the review
was 1415 participants. However, this represents only 55.2% of the
total population (n = 2560) reported in the included studies. Data
from 1145 participants were not available for use (n = 1050 ex-
cluded from Clionsky 2010, as only one of their five data sets were
included in the analysis for Mini-Cog test accuracy; and n = 95
excluded from Filho 2009 due to incomplete data or having more
than four years of formal education, as the study only included
those considered to have low levels of education). Clionsky 2010
reported the development and validation of a new cognitive test;
this process was based on using historic clinical data sets, and only
one of these data sets reported Mini-Cog test accuracy data, thus
the majority of participants in the study do not contribute data to
this review.
Clionsky 2010 included participants referred to neuropsychology
services for assessment; Filho 2009 recruited a selection of partic-
ipants attending for general medical treatment on an outpatient
basis; and Milian 2012 included individuals referred to a mem-
ory clinic. None of the studies evaluated Mini-Cog among general
hospital inpatients.
Key features of the studies are summarised in the Characteristics
of included studies table. Additional features of these studies are
also reported in Table 1.
One study did not report dementia subtype, using a binary classi-
fication of dementia versus no dementia (Filho 2009). The other
studies reported dementia subtype in more detail, however there
was some overlap in the categorisation of subtypes, making direct
comparison more challenging (Table 1). Alzheimer’s disease was
the most common subtype in 57.3%, Clionsky 2010, and 49.1%,
Milian 2012, of participants. The prevalence of dementia in the
study samples varied from 32.2% (95% confidence interval (CI)
26.3 to 38.8%), Filho 2009, to 87.3% (95% CI 84.1 to 89.9%),
Milian 2012, although important exclusions apply to the study
populations that impact these figures (e.g. exclusion of those with
mild cognitive impairment, depression or any other mental health
diagnoses or the need for participants to provide informed con-
sent). The descriptive variables of ethnicity, comorbidity, spectrum
of presenting symptoms, and ApoE status were not reported in any
of the included studies.
All studies utilised the original scoring system (Borson 2000).
Filho 2009 reported multiple thresholds to define Mini-Cog test
positivity and the impact of varying the threshold on sensitivity
and specificity. Data from the original scoring system are those
used to provide comparability between results.
Meta-analysis was planned to determine a summary pooled esti-
mate for the diagnostic test accuracy of Mini-Cog in identifying
dementia in secondary care settings. However, due to the method-
ological limitations and heterogeneity of included studies, we did
not perform quantitative synthesis. The extracted data, includ-
ing sensitivity, specificity, and likelihood ratios for each study, are
summarised in Summary of findings. A forest plot is presented in
Figure 3. The sensitivities of the Mini-Cog in the individual stud-
ies were reported as 0.67 (95% CI 0.63 to 0.71) (Clionsky 2010),
0.60 (95% CI 0.48 to 0.72) (Filho 2009), and 0.87 (95% CI
0.83 to 0.90) (Milian 2012). The specificity of the Mini-Cog for
each individual study was 0.87 (95% CI 0.81 to 0.92) (Clionsky
2010), 0.65 (95% CI 0.57 to 0.73) (Filho 2009), and 1.00 (95%
CI 0.94 to 1.00) (Milian 2012). Positive predictive values were
0.94 (Clionsky 2010), 0.45 (Filho 2009), and 1.00 (Milian 2012).
Negative predictive values were 0.49 (Clionsky 2010), 0.78 (Filho
2009), and 0.52 (Milian 2012).
Figure 3. Forest plot of individual study results using Mini-Cog in secondary care for the diagnosis of
dementia.
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One study reported test accuracy by dementia subtype, classifying
these as: all dementia, Alzheimer’s dementia, and non-Alzheimer’s
dementia (Milian 2012). Sensitivity was reported to be higher
for Alzheimer’s dementia (0.91 versus 0.87) and lower for non-
Alzheimer’s dementia (0.83 versus 0.87) compared to all demen-
tias, although the authors do not report formal statistical compar-
isons for these results (Milian 2012).
We did not perform planned subgroup analyses to investigate po-
tential sources of heterogeneity and sensitivity analyses due to the
methodological and clinical heterogeneity. Study characteristics
regarding prevalence of dementia, cut-points to determine a pos-
itive test, the reference standard used to diagnose dementia, and
the type of dementia are reported in Table 1. Severity of demen-
tia was not reported in any of the included studies. Study quality
is described above and in the Characteristics of included studies
table.
D I S C U S S I O N
Summary of main results
We found only three studies that evaluated the test accuracy of
the Mini-Cog in secondary care settings compared to a reference
standard assessment using recognised dementia diagnostic crite-
ria. Only 55.3% of available patient data was used to evaluate the
test accuracy of Mini-Cog. Our ’Risk of bias’ assessment identi-
fied concerns regarding both the internal and external validity of
the included studies. In all studies the Mini-Cog was retrospec-
tively derived from historic data sets. No studies included acute
general hospital inpatients. The prevalence of dementia ranged
from 32.2% to 87.3%. The sensitivities of the Mini-Cog in the
individual studies were reported as 0.67 (95% CI 0.63 to 0.71),
0.60 (95% CI 0.48 to 0.72), and 0.87 (95% CI 0.83 to 0.90).
The specificity of the Mini-Cog for each individual study was 0.87
(95% CI 0.81 to 0.92), 0.65 (95% CI 0.57 to 0.73), and 1.00
(95% CI 0.94 to 1.00). Positive predictive values were 0.94, 0.45,
and 1.00. Negative predictive values were 0.49, 0.78, and 0.52.
We did not perform meta-analysis due to the concerns regarding
risk of bias and heterogeneity.
Strengths and weaknesses of the review
We conducted the review following the published protocol (Chan
2014), with only limited differences (Differences between protocol
and review). The search strategy was robust and conducted by
an Information Specialist, using an approach common across the
Mini-Cog reviews. Study quality was formally evaluated using the
QUADAS-2 methodology (Appendix 2) and utilising anchoring
statements common across the Cochrane Dementia and Cognitive
Improvement Group suite of diagnostic test accuracy reviews (
Appendix 3).
Limitations of the review primarily reflect the lack of eligible stud-
ies for inclusion and heterogeneity of populations and methods.
These precluded the conduct of the prespecified analyses, includ-
ing evaluating dementia subtype and producing a summary of test
estimate Mini-Cog test accuracy in secondary care and more de-
tailed evaluation of the effect of heterogeneity on study findings.
We recognise that had the identified studies been more method-
ologically and clinically consistent, specific methods have been de-
veloped to allow meta-analysis of diagnostic test accuracy studies
when there are small numbers of studies identified for inclusion
(Takwoingi 2017). Finally, in common with other diagnostic test
accuracy reviews in dementia, the reliance on an imperfect refer-
ence standard is an important limitation to acknowledge.
Applicability of findings to the review question
This review sought to evaluate the test accuracy of the Mini-Cog
for detecting dementia in secondary care. None of the included
studies evaluated the Mini-Cog as a traditional test accuracy ap-
proach would anticipate: where the Mini-Cog would be conducted
and this would be followed by an independent and contemporane-
ous reference standard assessment to diagnose dementia. All three
studies retrospectively derived Mini-Cog from more lengthy neu-
ropsychological tests, which had the potential to introduce bias.
There is also potential for incorporation bias within the reference
standard, as the components of these tests may have helped inform
reference standard assessment. Finally, the three populations stud-
ied are non-consecutive with exclusions which affect the preva-
lence of dementia and applicability of results to current clinical
practice. As such, evaluation of the included studies make it diffi-
cult to answer the question underpinning this review.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The available studies have not considered use of Mini-Cog as a
stand-alone cognitive assessment compared to reference standard
diagnosis of dementia. The methodological limitations and het-
erogeneity, coupled with the small number of included studies,
means there is limited information to draw firm conclusions. The
results are inconsistent with respect to the pattern of test accuracy.
The currently available evidence thus does not support recom-
mending Mini-Cog as a short cognitive test for use in secondary
care settings. This finding is in-keeping with the evidence regard-
ing use of Mini-Cog in primary care, Seitz 2018, and community
settings, Fage 2015. A range of brief cognitive tests are available
and used in clinical practice (Velayudhan 2014), although with a
lack of empirical head-to-head data comparing their test accuracy.
Other cognitive tests, such as the Montreal Cognitive Assessment,
Davis 2015, or Mini-Mental State Examination, Creavin 2016,
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appear to have higher levels of sensitivity 0.94 (no 95% confidence
interval (CI) reported) and 0.85 (95% CI 0.74 to 0.92) respec-
tively, which may be desirable in a screening test. However, the
greater burden of testing associated with longer instruments needs
to be taken into account.
Implications for research
Future research should specifically evaluate the Mini-Cog as an
index test, rather than as part of a wider cognitive test battery, or
when authors are attempting to create a new diagnostic instru-
ment. Use of multiple different instruments and creation of new
tools is common across the dementia and cognitive impairment
literature, and potentially represents a barrier to research due to
lack of standardisation and heterogeneity of assessment (Harrison
2016).
Furthermore, the included studies did not address any feasibility
questions around use of Mini-Cog. Some studies specifically ex-
cluded those with sensory impairment or hand movement lim-
itations. Mini-Cog is a short cognitive test and thus may show
promise with respect to feasibility in practice. The ability of hos-
pitalised adult populations to complete diagnostic assessments is
a critical part of determining the applicability and usefulness of
a testing strategy in clinical practice and one that has been com-
monly overlooked in the dementia diagnostic test accuracy litera-
ture in secondary care (Elliott 2019; Harrison 2015; Lees 2017).
Authors conducting diagnostic test accuracy research in the de-
mentia field should utilise reporting guidance to help improve
transparency and allow a more complete critical evaluation of the
methodology employed (Noel-Storr 2014).
Finally, the aim of evaluating the test accuracy of tools to iden-
tify dementia is to improve diagnostic pathways to achieve better
outcomes for individuals using health and care services. Further
research is needed to evaluate the role of diagnostic strategies in
changing individual and population-level outcomes to ensure that
use of instruments is appropriate.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Clionsky 2010
Study characteristics
Patient sampling The study had access to 1752 patient records collated from 5 data sources from neuropsychology
and geriatric psychiatry practice. Sampling frame for record collection is not described. 702 records
collected between 2005 and 2008 were used to generate data evaluating Mini-Cog test accuracy
Patient characteristics and set-
ting
Records used in the analysis were collected in a neuropsychology setting where individuals were
referred by a physician or agency in the community. No inclusion or exclusion criteria are listed
Index tests Mini-Cog was retrospectively derived from results of the Mini-Mental State Examination (which
contains 3-item recall) and Clock Draw Test, so the index test was not conducted contemporaneously
as expected in the review question. Mini-Cog was scored according to original criteria in Borson
2000.
Target condition and reference
standard(s)
Clinical diagnosis of dementia was determined based on DSM-IV criteria by 1 of 6 licenced psy-
chologists. Patients were evaluated based on their age- and education-adjusted neuropsychological
test scores, medical and psychiatric history, and interview with a family informant
Flow and timing Study authors made use of 5 data sets to perform the retrospective analyses reported in the paper.
Those in neuropsychology received a different reference standard assessment to those assessed in
geriatric psychiatry. Reason for use of only 1 set of individuals assessed in neuropsychology for
calculation of test accuracy results not provided in the paper
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
High Unclear
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Clionsky 2010 (Continued)
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
No
High
Filho 2009
Study characteristics
Patient sampling Convenience sample of 306 recruited individuals, 65 years of age or older, seeking general medical
treatment as outpatients at Internal Medicine Clinic of the Policlínica Piquet Carneiro at Rio de
Janeiro State University Hospital. Sampling limited by the number of consenting individuals and
availability of research team to assess individuals each day. Occasionally, patients returned next
day to finish their testing. Final sample restricted only to those 211 individuals who had complete
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Filho 2009 (Continued)
assessment data and 4 or fewer years of schooling
Patient characteristics and set-
ting
Inclusion criteria included preserved hearing and comprehension to fully participate in the study
and sign an informed consent form. Exclusions were reports of a serious uncorrected visual or
auditory deficiency; being at an advanced stage of cognitive disturbance or having any mental illness
that could compromise understanding of and performance on the test procedures; having a native
language other than Portuguese; and difficulty in hand movement due to rheumatic or neurological
diseases
Index tests Multiple thresholds for defining a positive result using Mini-Cog are reported in the paper. These
include the methodology described by Borson 2000. Mini-Cog was not collected at the time of
patient assessment but derived retrospectively, so the index test was not conducted contemporane-
ously as expected in the review question
Target condition and reference
standard(s)
The diagnosis of dementia was made based on the formal criteria of DSM-IV, as agreed upon be-
tween geriatrician and neuropsychologist. This included clinical impression and neuropsychological
evaluation, including some components of the index tests
Flow and timing Neuropsychological assessments could be administered on different days. Patients who were lost in
follow-up and those who did not finish their evaluation were excluded. Those with more than 4
years of education were excluded from the analysis despite being assessed
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High High
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
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Filho 2009 (Continued)
If a threshold was used, was it
pre-specified?
Unclear
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
High
Milian 2012
Study characteristics
Patient sampling Participants selected retrospectively from all admitted patients to the Memory Clinic of the De-
partment of Psychiatry and Psychotherapy of the University Hospital of Tübingen between 2004
to 2009. Sampling frame is not described, but non-consecutive sample included based on exclusion
criteria
Patient characteristics and set-
ting
Sample composed of older adults with normal or corrected-to-normal visual acuity, “sufficient
hearing ability”, and a wide education range. Those described as having “severe handicap affecting
the ability to perform the required tasks”, mild cognitive impairment, or a depressive episode were
excluded from analysis in the study. Also, patients with underlying neurological and psychiatric
disorder unrelated to the diagnosis of dementia were excluded. Study was set in an inpatient memory
clinic in Germany of individuals referred for evaluation of cognition
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Milian 2012 (Continued)
Index tests Study participants completed the clock-drawing test and Mini-Mental State Examination (which
contains 3-item recall) as part of their assessment. This was done without knowledge of reference
standard diagnosis. However, the full index test (Mini-Cog) was retrospectively derived, so the index
test was not conducted contemporaneously as expected in the review question. Mini-Cog results
were scored in accordance with original scoring guidance from tool authors (Borson 2000).
Target condition and reference
standard(s)
Clinical diagnosis of dementia based on DSM-IV criteria, the ICD-10 of Mental and Behavioural
Disorders, and NINCDS-ADRDA. Index test results (from Mini-Cog) were not calculated at the
time of reference standard diagnosis. Other neuropsychological tests results were available and
informed reference standard diagnosis
Flow and timing Information to inform the index test and reference standard was collected contemporaneously as
part of a diagnostic assessment. The items used to derive the index test were collected prior to
completion of a reference standard diagnosis
Comparative
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High High
DOMAIN 2: Index Test All tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Unclear High
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Milian 2012 (Continued)
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
DSM-IV - Diagnostic and Statistical Manual of Mental Disorders, fourth edition; ICD-10 - International Classification of Dis-
eases, Tenth Revision; NINCDS-ADRDA - National Institute of Neurological and Communicative Disorders and Stroke and the
Alzheimer’s Disease and Related Disorders Association
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Borson 2000 Wrong setting - not in secondary care
Borson 2003 Wrong setting - not in secondary care
Borson 2005 Wrong setting - not in secondary care
Borson 2006 Wrong setting - not in secondary care
Carnero-Pardo 2013 Wrong setting - not in secondary care
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(Continued)
Carnero-Pardo 2019 Wrong outcome measure - not diagnosing dementia
Chen 2011 Participants did not receive gold standard evaluation using standardised diagnostic criteria
Dash 2004 Participants did not receive gold standard evaluation using standardised diagnostic criteria
Del Ser 2000 Study did not use Mini-Cog as index test.
Dougherty 2010 Wrong study design
Fuchs 2012 Wrong setting - not in secondary care
Geschke 2019 Participants did not receive gold standard evaluation using standardised diagnostic criteria
Holsinger 2012 Wrong setting - not in secondary care
McCarten 2012 Wrong setting - not in secondary care
Milian 2013 Duplicate publication/data
Sonnett 2012 Participants did not receive gold standard evaluation using standardised diagnostic criteria
Steenland 2008 Wrong study design
Wilber 2005 Participants did not receive gold standard evaluation using standardised diagnostic criteria
Wright 2011 Study did not use Mini-Cog as index test.
Yang 2016 Wrong setting - not in secondary care
Yang 2018 Wrong setting - not in secondary care
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D A T A
Presented below are all the data for all of the tests entered into the review.
Tests. Data tables by test
Test
No. of
studies
No. of
participants
1 Mini-Cog in secondary care 3 1415
Test 1. Mini-Cog in secondary care.
Review: Mini-Cog for the diagnosis of Alzheimer s disease dementia and other dementias within a secondary care setting
Test: 1 Mini-Cog in secondary care
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Clionsky 2010 346 24 170 162 0.67 [ 0.63, 0.71 ] 0.87 [ 0.81, 0.92 ]
Filho 2009 41 50 27 93 0.60 [ 0.48, 0.72 ] 0.65 [ 0.57, 0.73 ]
Milian 2012 380 0 58 64 0.87 [ 0.83, 0.90 ] 1.00 [ 0.94, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
A D D I T I O N A L T A B L E S
Table 1. Overview of study characteristics
Study ID Country Study par-
ticipants
(N)
Mean age
in years
(SD)
Female
gender %
Level of
education
Mini-Cog
scoring
Reference
standard
Demen-
tia preva-
lence N
(%; 95%
CI)
Dementia
subtype N
(%)
Clionsky
2010
USA 1752
records
available to
review au-
thors; 702
78.2 (7.2) 61.0 12.8 years
(+/−3.1)
As
per Borson
2000
DSM-IV 516 (73.5;
70.1 to 76.
6%)
Alzheimer’s
disease
402 (57.
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Table 1. Overview of study characteristics (Continued)
(40.1%)
records
from Neu-
ropsychol-
ogy Group
2
used to de-
scribe test
accuracy of
Mini-Cog
3); fron-
totemporal
dementia
71 (10.1)
; vascular
dementia
24 (3.4)
; mixed
or other
dementia
19 (2.7)
Filho 2009 Brazil 306; 211
(69.0%)
included in
anal-
ysis with 4
or fewer
years of ed-
ucation
Dementia
74.0 (5.8)
No demen-
tia 72.0 (5.
0)
72.5 Whole in-
cluded
sample ≤ 4
years
Multi-
ple thresh-
olds re-
ported in-
cluding
scoring as
per Borson
2000
DSM-IV 68 (32.2;
26.3 to 38.
8%)
Bi-
nary classi-
fication de-
mentia or
no demen-
tia, demen-
tia subtype
not
reported
Milian
2012
Germany 502; all
included in
analysis
Dementia
75.0 (8.5)
No cogni-
tive im-
pairment
73.1 (5.5)
61.4 ≤ 8 years:
47.7%;
9
to 11 years:
26.3%;
≥ 12 years:
26.0%
As
per Borson
2000
DSM-IV,
ICD-10,
NINCDS-
ADRDA
438 (87.3;
84.1 to 89.
9%)
Alzheimer’s
disease
215 (49.1)
; vascular
dementia
37 (8.4)
; vascu-
lar and
Alzheimer’s
disease 107
(24.4);
Parkinson’s
disease
dementia
10 (2.3)
; fron-
totemporal
lobar de-
generation
6 (1.4);
dementia
with Lewy
bodies
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Table 1. Overview of study characteristics (Continued)
6 (1.4)
; other
dementias
57 (13.0)
95% CI - 95% confidence interval; DSM-IV - Diagnostic and Statistical Manual of Mental Disorders, fourth edition; ICD-10 -
International Classification of Diseases, Tenth Revision; N - number; NINCDS-ADRDA - National Institute of Neurological and
Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association; SD - standard deviation
A P P E N D I C E S
Appendix 1. Sources searched and search strategies
Source and platform Search strategy Hits retrieved
Cochrane Dementia and Cognitive Im-
provement Group DTA register
(see bottom of this table for more informa-
tion in the search narrative)
[Date of most recent search 12 March
2019]
1. “mini-Cog” [all fields]
2. minicog [all fields]
3. (MCE and (cognit* OR dement* OR
screen* OR Alzheimer*)) [all fields]
3. or/1-3
Sept 2012: 452
Jul 2013: 34
Feb 2015: 7
Mar 2019: 7
MEDLINE In-Process and Other Non-In-
dexed Citations and MEDLINE 1950 to
present (OvidSP)
[Date of most recent search 12 March
2019]
1. “mini-Cog”.ti,ab.
2. minicog.ti,ab.
3. (MCE and (cognit* OR dement* OR
screen* OR Alzheimer*)).ti,ab
3. or/1-3
Sept 2012: 91
Jul 2013: 12
Feb 2015: 31
Mar 2019: 67
Embase
1974 to 11 March 2019 (OvidSP)
[Date of most recent search 12 March
2019]
1. “mini-cog*”.mp.
2. minicog*.mp.
3. (MCE and (cognit* OR dement* OR
screen* OR Alzheimer*)).ti,ab
4. or/1-3
Sept 2012: 96
Jul 2013: 37
Feb 2015: 80
Mar 2019: 205
PsycINFO
January 1806 - 11 March 2019 (OvidSP)
[Date of most recent search 12 March
2019]
1. minicog*.mp.
2. “mini-cog*”.mp.
3. 1 or 2
4. 2012*.up. OR 2013*.up.
5. 3 AND 4
Sept 2012: 69
Jul 2013: 28
Feb 2015: 50
Mar 2019: 49
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(Continued)
BIOSIS Citation Index 1926 to present
(ISI Web of Science)
[Date of most recent search 12 March
2019]
Topic=(“mini-cog*” OR “minicog*” OR
(MCE AND dement*) OR (MCE AND
alzheimer*))
Sept 2012: 33
Jul 2013: 7
Feb 2015: 9
Mar 2019: 25
Web of Science Core Collection (1945 to
present) (ISI Web of Science)
[Date of most recent search 12 March
2019]
Topic=(“mini-cog*” OR “minicog*” OR
(MCE AND dement*) OR (MCE AND
alzheimer*))
Sept 2012: 93
Jul 2013: 20
Feb 2015: 35
Mar 2019: 102
LILACS (BIREME)
[Date of most recent search 12 March
2019]
“mini-cog” OR minicog OR (MCE AND
dementia) OR (MCE AND demencia) OR
(MCE AND demência) OR (MCE AND
alzheim$)
Sept 2012: 2
Jul 2013: 2
Feb 2015: 2
Mar 2019: 13
Total before automated de-duplication 1658
Total after automated de-duplication and first assessment 468
Search narrative: the searches focus on a single concept - the index test. However, in order to ensure additional sensitivity, a broad
search for neuropsychological and cognitive tests is run to populate the Cochrane Dementia and Cognitive Improvement Group’s
DTA register. This search is run every six months in MEDLINE and Embase (OvidSP). The most recent search was run in February
2019. The MEDLINE search can be seen below:
1. “word recall”.ti,ab.
2. (“7-minute screen” or “seven-minute screen”).ti,ab.
3. (“6 item cognitive impairment test” or “six-item cognitive impairment test”).ti,ab.
4. “6 CIT”.ti,ab.
5. “AB cognitive screen”.ti,ab.
6. “abbreviated mental test”.ti,ab.
7. “ADAS-cog”.ti,ab.
8. AD8.ti,ab.
9. “inform* interview”.ti,ab.
10. “animal fluency test”.ti,ab.
11. “brief alzheimer* screen”.ti,ab.
12. “brief cognitive scale”.ti,ab.
13. “clinical dementia rating scale”.ti,ab.
14. “clinical dementia test”.ti,ab.
15. “community screening interview for dementia”.ti,ab.
16. “cognitive abilities screening instrument”.ti,ab.
17. “cognitive assessment screening test”.ti,ab.
18. “cognitive capacity screening examination”.ti,ab.
19. “clock drawing test”.ti,ab.
20. “deterioration cognitive observee”.ti,ab.
21. (“Dem Tect” or DemTect).ti,ab.
22. “object memory evaluation”.ti,ab.
23. “IQCODE”.ti,ab.
24. “mattis dementia rating scale”.ti,ab.
25. “memory impairment screen”.ti,ab.
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(Continued)
26. “minnesota cognitive acuity screen”.ti,ab.
27. “mini-cog”.ti,ab.
28. “mini-mental state exam*”.ti,ab.
29. “mmse”.ti,ab.
30. “modified mini-mental state exam”.ti,ab.
31. “3MS”.ti,ab.
32. “neurobehavio?ral cognitive status exam*”.ti,ab.
33. “cognistat”.ti,ab.
34. “quick cognitive screening test”.ti,ab.
35. “QCST”.ti,ab.
36. “rapid dementia screening test”.ti,ab.
37. “RDST”.ti,ab.
38. “repeatable battery for the assessment of neuropsychological status”.ti,ab.
39. “RBANS”.ti,ab.
40. “rowland universal dementia assessment scale”.ti,ab.
41. “rudas”.ti,ab.
42. “self-administered gerocognitive exam*”.ti,ab.
43. (“self-administered” and “SAGE”).ti,ab.
44. “self-administered computerized screening test for dementia”.ti,ab.
45. “short and sweet screening instrument”.ti,ab.
46. “sassi”.ti,ab.
47. “short cognitive performance test”.ti,ab.
48. “syndrome kurztest”.ti,ab.
49. (“six item screener” or “6-item screener”).ti,ab.
50. “short memory questionnaire”.ti,ab.
51. (“short memory questionnaire” and “SMQ”).ti,ab.
52. “short orientation memory concentration test”.ti,ab.
53. “s-omc”.ti,ab.
54. “short blessed test”.ti,ab.
55. “short portable mental status questionnaire”.ti,ab.
56. “spmsq”.ti,ab.
57. “short test of mental status”.ti,ab.
58. “telephone interview of cognitive status modified”.ti,ab.
59. “tics-m”.ti,ab.
60. “trail making test”.ti,ab.
61. “verbal fluency categories”.ti,ab.
62. “WORLD test”.ti,ab.
63. “general practitioner assessment of cognition”.ti,ab.
64. “GPCOG”.ti,ab.
65. “Hopkins verbal learning test”.ti,ab.
66. “HVLT”.ti,ab.
67. “time and change test”.ti,ab.
68. “modified world test”.ti,ab.
69. “symptoms of dementia screener”.ti,ab.
70. “dementia questionnaire”.ti,ab.
71. “7MS”.ti,ab.
72. (“concord informant dementia scale” or CIDS).ti,ab.
73. (SAPH or “dementia screening and perceived harm*”).ti,ab.
74. or/1-73
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(Continued)
75. exp Dementia/
76. Delirium, Dementia, Amnestic, Cognitive Disorders/
77. dement*.ti,ab.
78. alzheimer*.ti,ab.
79. AD.ti,ab.
80. (“lewy bod*” or DLB or LBD or FTD or FTLD or “frontotemporal lobar degeneration” or “frontaltemporal dement*”).ti,ab.
81. “cognit* impair*”.ti,ab.
82. (cognit* adj4 (disorder* or declin* or fail* or function* or degenerat* or deteriorat*)).ti,ab.
83. (memory adj3 (complain* or declin* or function* or disorder*)).ti,ab.
84. or/75-83
85. exp “sensitivity and specificity”/
86. “reproducibility of results”/
87. (predict* adj3 (dement* or AD or alzheimer*)).ti,ab.
88. (identif* adj3 (dement* or AD or alzheimer*)).ti,ab.
89. (discriminat* adj3 (dement* or AD or alzheimer*)).ti,ab.
90. (distinguish* adj3 (dement* or AD or alzheimer*)).ti,ab.
91. (differenti* adj3 (dement* or AD or alzheimer*)).ti,ab.
92. diagnos*.ti.
93. di.fs.
94. sensitivit*.ab.
95. specificit*.ab.
96. (ROC or “receiver operat*”).ab.
97. Area under curve/
98. (“Area under curve” or AUC).ab.
99. (detect* adj3 (dement* or AD or alzheimer*)).ti,ab.
100. sROC.ab.
101. accura*.ti,ab.
102. (likelihood adj3 (ratio* or function*)).ab.
103. (conver* adj3 (dement* or AD or alzheimer*)).ti,ab.
104. ((true or false) adj3 (positive* or negative*)).ab.
105. ((positive* or negative* or false or true) adj3 rate*).ti,ab.
106. or/85-105
107. exp dementia/di
108. Cognition Disorders/di [Diagnosis]
109. Memory Disorders/di
110. or/107-109
111. *Neuropsychological Tests/
112. *Questionnaires/
113. Geriatric Assessment/mt
114. *Geriatric Assessment/
115. Neuropsychological Tests/mt, st
116. “neuropsychological test*”.ti,ab.
117. (neuropsychological adj (assess* or evaluat* or test*)).ti,ab.
118. (neuropsychological adj (assess* or evaluat* or test* or exam* or battery)).ti,ab.
119. Self report/
120. self-assessment/ or diagnostic self evaluation/
121. Mass Screening/
122. early diagnosis/
123. or/111-122
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(Continued)
124. 74 or 123
125. 110 and 124
126. 74 or 123
127. 84 and 106 and 126
128. 74 and 106
129. 125 or 127 or 128
130. exp Animals/ not Humans.sh.
131. 129 not 130
Appendix 2. Assessment of methodological quality table QUADAS-2 tool
Domain Patient selection Index test Reference standard Flow and timing
Description Describe methods of pa-
tient selection: describe
included patients (prior
testing, presentation, in-
tended use of index test
and setting)
Describe the index test
and how it was con-
ducted and interpreted
Describe the reference
standard and how it
was conducted and in-
terpreted
Describe any patients
who did not receive the
index test(s) and/or ref-
erence standard or who
were excluded from the
2 x 2 table (refer to flow
diagram): describe the
time interval and any in-
terventions between in-
dex test(s) and reference
standard
Signalling questions
(yes, no, unclear)
Was a consecutive or ran-
dom sample of patients
enrolled?
Was a case-control de-
sign avoided?
Did the study avoid in-
appropriate exclusions?
Were the index test re-
sults interpreted without
knowledge of the results
of the reference stan-
dard?
If a threshold was used,
was it prespecified?
Is the reference standard
likely to correctly classify
the target condition?
Were the reference stan-
dard results interpreted
without knowledge of
the results of the index
test?
Was there an appropri-
ate interval between in-
dex test(s) and reference
standard?
Did all patients receive
the same reference stan-
dard?
Were all patients in-
cluded in the analysis?
Risk of bias
(high, low, unclear)
Could the selection of
patients have introduced
bias?
Could the conduct or in-
terpretation of the in-
dex test have introduced
bias?
Could the reference stan-
dard, its conduct, or its
interpretation have in-
troduced bias?
Could the patient flow
have introduced bias?
Concerns regarding ap-
plicability
(high, low, unclear)
Are there concerns that
the included patients do
not match the review
question?
Are there concerns that
the index test, its con-
duct, or its interpreta-
tion differ from the re-
view question?
Are there concerns that
the target condition as
defined by the reference
standard does not match
the review question?
-
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Appendix 3. Anchoring statements to assist with assessment of risk of bias
Domain 1: patient selection
Risk of bias: could the selection of patients have introduced bias? (high, low, unclear)
Was a consecutive or random sample of patients enrolled?
Where sampling is used, the methods least likely to cause bias are consecutive sampling or random sampling, which should be stated
and/or described. Non-random sampling or sampling based on volunteers is more likely to be at high risk of bias.
Was a case-control design avoided?
Case-control study designs have a high risk of bias, but are sometimes the only studies available especially if the index test is expensive
and/or invasive. Nested case-control designs (systematically selected from a defined population cohort) are less prone to bias, but they
will still narrow the spectrum of patients that receive the index test. Study designs (both cohort and case-control) that may also increase
bias are those designs where the study team deliberately increase or decrease the proportion of participants with the target condition,
for example a population study may be enriched with extra dementia participants from a secondary care setting.
Did the study avoid inappropriate exclusions?
We will automatically grade the study as unclear if exclusions are not detailed (pending contact with study authors). Where exclusions are
detailed, the study will be graded as ’low risk’ if the review authors consider the exclusions to be appropriate. Certain exclusions common
to many studies of dementia are: medical instability; terminal disease; alcohol/substance misuse; concomitant psychiatric diagnosis;
other neurodegenerative condition. However, if ’difficult to diagnose’ groups are excluded this may introduce bias, so exclusion criteria
must be justified. For a community sample we would expect relatively few exclusions. We will label post hoc exclusions ’high risk’ of
bias.
Applicability: are there concerns that the included patients do not match the review question? (high, low, unclear)
The included patients should match the intended population as described in the review question. If not already specified in the review
inclusion criteria, setting will be particularly important - the review authors should consider population in terms of symptoms; pre-
testing; potential disease prevalence. We will classify studies that use very selected participants or subgroups as having low applicability,
unless they are intended to represent a defined target population, for example people with memory problems referred to a specialist
and investigated by lumbar puncture.
Domain 2: index test
Risk of bias: could the conduct or interpretation of the index test have introduced bias? (high, low, unclear)
Were the index test results interpreted without knowledge of the reference standard?
Terms such as ’blinded’ or ’independently and without knowledge of ’ are sufficient; full details of the blinding procedure are not
required. This item may be scored as ’low risk’ if explicitly described or if there is a clear temporal pattern to the order of testing that
precludes the need for formal blinding, that is all (neuropsychological test) assessments were performed before the dementia assessment.
As most neuropsychological tests are administered by a third party, knowledge of dementia diagnosis may influence their ratings; tests
that are self-administered, for example using a computerised version, may have less risk of bias.
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Were the index test thresholds prespecified?
For neuropsychological scales there is usually a threshold above which participants are classified as ’test positive’; this may be referred
to as threshold, clinical cut-off, or dichotomisation point. Different thresholds are used in different populations. A study is classified
as at higher risk of bias if the authors define the optimal cut-off post hoc based on their own study data. Certain papers may use an
alternative methodology for analysis that does not use thresholds, and these papers should be classified as not applicable.
Were sufficient data on (neuropsychological test) application given for the test to be repeated in an independent study?
Particular points of interest include method of administration (e.g. self-completed questionnaire versus direct questioning interview);
nature of informant; language of assessment. If a novel form of the index test is used, for example a translated questionnaire, details of
the scale should be included and a reference given to an appropriate descriptive text, and there should be evidence of validation.
Applicability: are there concerns that the index test, its conduct, or its interpretation differ from the review question? (high,
low, unclear)
Variations in the length, structure, language, and/or administration of the index test may all affect applicability if they vary from those
specified in the review question.
Domain 3: reference standard
Risk of bias: could the reference standard, its conduct, or its interpretation have introduced bias? (high, low, unclear)
Is the reference standard likely to correctly classify the target condition?
Commonly used international criteria to assist with clinical diagnosis of dementia include those detailed in the Diagnostic and Statistical
Manual of Mental Disorders IV (DSM-IV) and 10th Revision of the International Classification of Diseases (ICD-10). Criteria specific
to dementia subtypes include but are not limited to National Institute of Neurological and Communicative Disorders and Stroke and
the Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) criteria for Alzheimer’s dementia; McKeith criteria
for Lewy body dementia; Lund criteria for frontotemporal dementias; and the National Institute of Neurological Disorders and Stroke
and Association Internationale pour la Recherché et l’Enseignement en Neurosciences (NINDS-AIREN) criteria for vascular dementia.
Where the criteria used for assessment are not familiar to the review authors and the Cochrane Dementia and Cognitive Improvement
Group, this item should be classified as ’high risk of bias’.
Were the reference standard results interpreted without knowledge of the results of the index test?
Terms such as ’blinded’ or ’independent’ are sufficient; full details of the blinding procedure are not required. This may be scored as
’low risk’ if explicitly described or if there is a clear temporal pattern to order of testing, that is all dementia assessments performed
before (neuropsychological test) testing.
Informant rating scales and direct cognitive tests present certain problems. It is accepted that informant interview and cognitive testing is
a usual component of clinical assessment for dementia, however specific use of the scale under review in the clinical dementia assessment
should be scored as high risk of bias.
Was sufficient information on the method of dementia assessment given for the assessment to be repeated in an independent
study?
Particular points of interest for dementia assessment include the training and expertise of the assessor; whether additional information
was available to inform the diagnosis (e.g. neuroimaging, other neuropsychological test results); and whether this was available for all
participants. High risk of bias if method of dementia assessment not described.
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Applicability: are there concerns that the target condition as defined by the reference standard does not match the review
question? (high, low, unclear)
It is possible that some methods of dementia assessment, although valid, may diagnose a far smaller or larger proportion of participants
with disease than in usual clinical practice. For example, the current reference standard for vascular dementia may underdiagnose
compared to usual clinical practice. In this instance the item should be rated as having poor applicability.
Domain 4: patient flow and timing
Risk of bias: could the patient flow have introduced bias? (high, low, unclear)
Was there an appropriate interval between the index test and reference standard?
For a cross-sectional study design, there is potential for the participant to change between assessments, however dementia is a slowly
progressive disease that is not reversible. The ideal scenario would be a same-day assessment, but longer periods of time (e.g. several
weeks or months) are unlikely to lead to a high risk of bias. For delayed-verification studies, the index and reference tests are necessarily
separated in time given the nature of the condition.
Did all participants receive the same reference standard?
There may be scenarios where participants who score ’test positive’ on the index test have a more detailed assessment for the target
condition. Where dementia assessment (or reference standard) differs between participants, this should be classified as high risk of bias.
Were all participants included in the final analysis?
Attrition will vary with study design. Delayed-verification studies will have higher attrition than cross-sectional studies due to mortality,
and it is likely to be greater in participants with the target condition. Dropouts (and missing data) should be accounted for. Attrition
that is higher than expected (compared to other similar studies) should be treated as high risk of bias. We have defined a cut-off of
greater than 20% attrition as being high risk, but this will be highly dependent on the length of follow-up in individual studies.
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The protocol stated in ’Selection of studies’ that studies had to: “Report estimates of test reproducibility, if completed within the study”.
In response to peer reviewers’ comments, this text was moved to the data extraction section as it was not a mandatory item to determine
study eligibility.
We updated statistical analysis text, as some studies did not provide numbers of true and false positives and negatives, but gave summary
test accuracy data which was entered into Review Manager 5.
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